Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects

Expert Opinion on Drug Safety

Volumn 11, Issue 5, 2012, Pages 753-766

  Cicero, Arrigo F G ^a   Ferroni, Alienor ^a   Ertek, Sibel ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Turkish Ministry of Health anliurfa Education and Research Hospital   (Turkey)

Author keywords

adverse effects; dyslipidemia; hyperlipidemia; nutraceuticals; safety; tolerability

Indexed keywords

ALPHA TOCOPHEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTILIPEMIC AGENT; BERBERINE; CARBAMAZEPINE; CHOLESTEROL 7ALPHA MONOOXYGENASE; DARUNAVIR; DIGOXIN; GARLIC EXTRACT; GUGGULSTERONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRON; ISPAGULA; LITHIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANNAN; MONACOLINE; NUTRACEUTICAL; OMEGA 3 FATTY ACID; ORAL ANTIDIABETIC AGENT; PHYTOSTEROL; POLICOSANOL; PROBIOTIC AGENT; SAQUINAVIR; SOYBEAN PROTEIN; STEROID; TRIACYLGLYCEROL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ANTICOAGULATION; BILE ACID SYNTHESIS; CHOLESTEROL BLOOD LEVEL; COMMIPHORA; DIET SUPPLEMENTATION; DIETARY FIBER; DISEASE EXACERBATION; DIVERTICULITIS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GARLIC; GENE EXPRESSION; HALITOSIS; HUMAN; INTESTINE FLORA; LD 50; META ANALYSIS (TOPIC); MONASCUS PURPUREUS; NONHUMAN; PATIENT COMPLIANCE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SIDE EFFECT; STOMACH DISCOMFORT; TEA; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; HUMANS; HYPOLIPIDEMIC AGENTS; META-ANALYSIS AS TOPIC; RISK FACTORS;

EID: 84865482955     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.705827     Document Type: Review

References (121)

1. Banegas JR, Lopez-Garcia E, Dallongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011;32:2143-52
2. Saha S, Gerdtham UG, Johansson P. Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases. Int J Environ Res Public Health 2010;7:3150-95
3. King DE, Mainous AG III, Matheson EM, Everett CJ. Impact of healthy lifestyle on mortality in people with normal blood pressure, LDL cholesterol, and C-reactive protein. Eur J Cardiovasc Prev Rehabil 2011; Epub ahead of print
4. Cicero AFG, Derosa G, D'angelo A, et al. Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives. Blood Press 2009;18:111-16
5. Cicero AFG, Ertek S. Natural sources of antidyslipidaemic agents: is there an evidence-based approach for their prescription? Med J Nutr Metab 2008;1(2):85-93
6. NCEP expert panel. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97
7. Catapano AL, Reiner Z, De Backer G, et al. European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217:3-46
8. Hasani-Ranjbar S, Nayebi N, Moradi L, et al. The efficacy and safety of herbal medicines used in the treatment of hyperlipidemia: a systematic review. Curr Pharm Res 2010;16:2935-47
9. McGowan MP, Proulx S. Nutritional supplements and serum lipids: doeas anything work? Curr Atheroscler Rep 2009;11:470-6
10. Kim JY, Kwon O. Culinary plants and their potential impact on metabolic overload. Ann NY Acad Sci 2011;1229:133-9
11. Vergara-Jimenez M, Conde K, Erickson SK, Fernandez ML. Hypolipidemic mechanisms of pectin and pysllium in guinea pigs fed high fat-sucrose diets: alterations on hepatic cholesterol metabolism. J Lipid Res 1998;39:1455-65 (Pubitemid 28332480)
12. Wei ZH, Wang H, Chen XY, et al. Time- and dose-dependent effect of psylium on serum lipids in mild-to-moderate hypercholesterolemia: a meta-analysis of controlled trials. Eur J Clin Nutr 2009;63:821-7
13. Maciejko JJ, Brazg R, Shah A, et al. Psyllium for the reduction of cholestyramine-associated gastrointestinal symptoms in the treatment of primary hypercholesterolemia. Arch Fam Med 1994;3:955-60
14. Shrestha S, Freake HC, McGrane MM, et al. A combination of psyllium and plant sterols alters lipoprotein metabolism in hypercholesterolemic subjects by modifying the intravascular processing of lipoproteins and increasing LDL uptake. J Nutr 2007;137:1165-70 (Pubitemid 46701906)
15. Moreyra AE, Wilson AC, Koraym A. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med 2005;165:1161-6 (Pubitemid 40720741)
16. Mechanick JI, Brett EM, Chausmer AB, et al. AACE Nutrition Guidelines Taskforce. American Association of Clinical Endocrinologists Medical Guidelines for the clinical use of dietary supplements and nutraceuticals. Endocr Pract 2003;9:417-70
17. Keithley J, Swanson B. Glucomannan and obesity: a critical review. Altern Ther Health Med 2005;11:30-4 (Pubitemid 43885299)
18. Yoshida M, Vanstone CA, Parsons WD, et al. Effect of plant sterols and glucomannan on lipids in individuals with and without type 2 diabetes. Eur J Clin Nutr 2006;60:529-37
19. Morgan LM, Tredger JA, Wright J, Marks V. The effect of soluble- and insoluble-fibre supplementation on post-prandial glucose tolerance, insulin and gastric inhibitory polypeptide secretion in healthy subjects. Br J Nutr 1990;64:103-10 (Pubitemid 20261539)
20. Vuksan V, Sievenpiper JL, Xu Z, et al. Konjac-Mannan and American ginsing: emerging alternative therapies for type 2 diabetes mellitus. J Am Coll Nutr 2001;20(S5):370S-80S (Pubitemid 32951814)
21. McCarty MF. Glucomannan minimizes the postprandial insulin surge: a potential adjuvant for hepatothermic therapy. Med Hypotheses 2002;58(6):487-90
22. Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr 2008;88(4):1167-75
23. Martino F, Martino E, Morrone F, et al. Effect of dietary supplementation with glucomannan on plasma total cholesterol and low density lipoprotein cholesterol in hypercholesterolemic children. Nutr Metab Cardiovasc Dis 2005;15:174-80 (Pubitemid 40934161)
24. Vega-Lopez S, Freake HC, Fernandez ML. Sex and hormonal status modulate the effects of psyllium on plasma lipids and monocyte gene expression in humans. J Nutr 2003;133:67-70 (Pubitemid 36070578)
25. Chua M, Baldwin TC, Hocking TJ, Chan K. Traditional uses and potential health benefits of Amorphophallus konjac K. Koch ex N.E.Br. J Ethnopharmacol 2010;128:268-78
26. Villaverde AF, Benlloch S, Berenguer M, et al. Acute hepatitis of cholestatic type possibly associated with the use of glucomannan (Amorphophalus konjac). J Hepatol 2004;41(6):1061-2 (Pubitemid 39575678)
27. Vanderbeek PB, Fasano C, O'Malley G, Hornstein J. Esophageal obstruction from a hygroscopic pharmacobezoar containing glucomannan. Clin Toxicol 2007;45:80-2
28. Mogadishian MH, McManus BM, Godin DV, et al. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. Circulation 1999;99: 1733-9 (Pubitemid 29162487)
29. Grundy SM. Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. Am J Cardiol 2005;96(Suppl):47D-50D (Pubitemid 40898170)
30. Mensink RP, de Jong A, Lutjohann D, et al. Plant stenols dose dependently decrease LDL cholesterol concentrations but not cholesterol standardized fat soluble antioxidant concentrations, at intakes up to 9 g/d. Am J Clin Nutr 2010;92:24-33
31. Moruisi KG, Oosthuizen W, Opperman AM. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. J Am Coll Nutr 2006;25:41-8 (Pubitemid 46939861)
32. Scholle JM, Baker WL, Talati R, Coleman CI. The effect of adding plant sterols or stanols to statin therapy in hypercholesterolemic patients: systematic review and meta-analysis. J Am Coll Nutr 2009;28:517-24
33. Yu L. The structure and function of niemann-pick C1-like 1 protein. Curr Opin Lipidol 2008;19(3):263-9 (Pubitemid 351653564)
34. Guardamagna O, Abello F, Baracco V, et al. Primary hyperlipidemias in children: effect of plant sterol supplementation on plasma lipids and markers of cholesterol synthesis and absorption. Acta Diabetol 2011;48:127-33
35. Weingartner O, Lutjohann D, Ji S, et al. Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol 2008;51(16):1553-61 (Pubitemid 351512314)
36. Weingartner O, Bohm M, Laufs U. Controversial role of plant sterol esters in the management of hypercholesterolaemia. Eur Heart J 2009;30(4):404-9.37
37. Weingartner O, Ulrich C, Lutjohann D, et al. Differential effects on inhibition of cholesterol absorption by plant stanol and plant sterol esters in apoE-/-mice. Cardiovasc Res 2011;90(3):484-92
38. Gylling H, Hallikainen M, Nissinen MJ, Miettinen TA. The effect of a very high daily plant stanol ester intake on serum lipids, carotenoids, and fat soluble vitamins. Clin Nutr 2010;29:112-18
39. Guo Z, Liu XM, Zhang QX, et al. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2011;21:844-50
40. Burcelin R, Luche E, Serino M, Amar J. The gut microbiota ecology: new opportunity for the treatment of metabolic diseases? Front Biosci 2009;14:5107-17
41. Klaver FA, van der Meer V. The assumed assimilation of cholesterol by Lactobacilli and Bifidobacterium bifidum is due to their bile salt-deconjugating activity. Appl Environ Microbiol 1999;59:1120-4
42. Grill JP, Cayuela C, Antoine JM, Schneider F. Effects of Lactobacillus amylovorus and Bifidobacterium breve on cholesterol. Lett Appl Microbiol 2000;31:154-6 (Pubitemid 30659000)
43. Brashears MM, Gilliland SE, Buck LM. Bile salt deconjugation and cholesterol removal from media by Lactobacillus casei. J Diary Sci 1998;81:2103-10 (Pubitemid 128445908)
44. Kumar M, Nagpal R, Kumar R, et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res 2012;2012:902-17
45. Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009;58(8):1091-103
46. Liu ZL, Liu JP, Zhang AL, et al. Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst Rev 2011(7):CD008305
47. Cicero AFG, Brancaleoni M, Laghi L, et al. Antihyperlipidaemic effect of a monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complement Ther Med 2005;13:273-8 (Pubitemid 43032955)
48. Keithley JK, Swanson B, Sha BE, et al. A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition 2002;18:201-4 (Pubitemid 34158685)
49. Gheit O, Sheashaa H, Abdelsalam M, et al. Efficacy and safety of monascus purpureus went rice in subjects with secondary hyperlipidemia. Eur J Intern Med 2009;20:e57-61
50. Liu J, Zhang J, Shi Y, et al. Chinese red yeast rice (monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 2006;1:4
51. Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010;105(2):198-204
52. Nijjar PS, Burke FM, Bloesch A, Rader DJ. Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol 2010;4(4):248-58
53. Grieco A, Miele L, Pompili M, et al. A cute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all. J Hepatol 2009;50:1273-7
54. Wigger-Alberti W, Bauer A, Hipler UC, Elsner P. Anaphylaxis due to monascus purpureus fermented rice (red yeast rice). Allergy 1999;54:1330-1 (Pubitemid 30070326)
55. In YL, Wang TH, Lee MH, Su NW. Biologically active components and nutraceuticals in monascus-fermented rice: a review. Appl Microbiol Biotechnol 2008;77:965-73
56. Eisenbrand G. Toxicological evaluation of red mould rice. Mol Nutr Food Res 2006;50:322-7
57. Gordon RY, Becker DJ. The role of red yeast rice for the physician. Curr Atheroscler Rep 2011;13:73-80
58. Monograph. Monascus purpureus (red yeast rice). Altern Med Rev 2004;9:208-10
59. Marinangeli CP, Jones PJ, Kassis AN, Eskin MN. Policosanols as nutraceuticals: fact or fiction. Crit Rev Food Sci Nutr 2010;50:259-67
60. Ng CH, Leung KY, Huang Y, Chen ZY. Policosanol has no antioxidant activity in human low-density lipoprotein but increases excretion of bile acids in hamsters. J Agric Food Chem 2005;5:6289-93 (Pubitemid 41169375)
61. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002;143:356-65
62. Castano G, Mas R, Fernandez L, et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolemia. Drugs Aging 2003;20:153-63 (Pubitemid 36246297)
63. Berthold HK, Unverdorben S, Degenhardt R, et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized, controlled trial. JAMA 2006;295:2262-9 (Pubitemid 43736576)
64. Singh DK, Li L, Porter TD. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther 2006;318:1020-6 (Pubitemid 44268306)
65. Guardamagna O, Abello F, Baracco V, et al. The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis 2011;21:424-9
66. Ackermann RT, Mulrow CD, Ramirez G, et al. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med 2001;161:813-24 (Pubitemid 32225389)
67. Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia: a meta-analysis of randomized clinical trials. Ann Intern Med 2000;133:420-9
68. Macan H, Uykimpang R, Alconcel M, et al. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr 2006;136(3 Suppl):793S-5S (Pubitemid 43363777)
69. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs. A systematic review. Drugs 2001;61:2163-75 (Pubitemid 34074799)
70. Berginc K, Milisav I, Kristl A. Garlic flavonoids and organosulfur compounds: impact on the hepatic pharmacokinetics of saquinavir and darunavir. Drug Metab Pharmacokinet 2010;25(6):521-30
71. Potter SM. Overview of proposed mechanisms for the hypocholesterolemic effect of soy. J Nutr 1995;125(3 Suppl):606S-11S
72. Torres N, Torre-Villalvazo I, Tovar AR. Regulation of lipid metabolism by soyprotein and its implication in diseases mediated by lipid disorders. J Nutr Biochem 2006;17:365-73 (Pubitemid 44250959)
73. Mullen E, Brown RM, Osborne TF, Shay NF. Soy isoflavones affect sterol regulatory element binding proteins (SREBPs) and SREBP-regulated genes in HepG2 cells. J Nutr 2004;134:2942-7 (Pubitemid 39470066)
74. Sirtori CR, Lovati MR. Soy proteins and cardiovascular disease. Curr Atheroscler Rep 2001;3:47-53
75. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995;333:276-82
76. Lenz TL. Therapeutic lifestyle changes and pharmaceutical care in the treatment of dyslipidemias in adults. J Am Pharm Assoc 2005;45(4):492-9
77. Harland JI, Haffner TA. Systematic review, meta-analysis and regression of randomized controlled trials reporting an association between an intake of circa 25 g soya protein per day and blood cholesterol. Atherosclerosis 2008;200:13-27
78. Weghuber D, Widhalm K. Effect of 3 month treatment of children and adolescents with familial and polygenic hypercholesterolemia with a soy-substituted diet. Br J Nutr 2008;99:281-6
79. Chen ST, Ferng SH. Yang CS, et al. variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients. Am J Kidney Dis 2005;46:1099-106
80. Hutchins AM, McIver IE, Johnston CS. Hypertensive crisis associated with high dose soy isoflovane supplementation in a post-menopausal woman; a case report. BMC Womens Health 2005;5:9
81. Cambria-Kiely JA. Effect of soy milk on warfarin. Ann Pharmacother 2002;36:1893-6
82. Anderson GD, Rosito G, Mohustsy MA, Elmer GW. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol 2003;43:643-8 (Pubitemid 36613123)
83. Cicero AFG, Ertek S. Berberine: metabolic and cardiovascular effects in preclinical and clinical trials. Nutr Diet Suppl 2009;1:1-10
84. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10:1344-51 (Pubitemid 40022716)
85. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008;57:712-17 (Pubitemid 351608234)
86. Cicero AFG, Rovati L, Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents in humans. Arzneimittel-Forschung Drug Res 2007;57:26-30 (Pubitemid 46212985)
87. Sabir M, Bhide NK. Study of some pharmacological actions of berberine. Indian J Physiol Pharmacol 1971;15:111-32
88. Kupeli E, Kosar M, Yesilada E, et al. A comparative study on the anti-inflammatory, antinociceptive and antipyretic effects of isoquinoline alkaloids from the roots of Turkish berberis species. Life Sci 2002; 72:645-57 (Pubitemid 35441232)
89. Affuso F, Mercurio V, Fazio V, Fazio S. Cardiovascular and metabolic effects of berberine. World J Cardiol 2010;2(4):71-7
90. Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonat 1993;63:201-8 (Pubitemid 23170617)
91. Xin HW, Wu XC, Li Q, et al. The effects of berberine on the pharmacokinetics of cyclosporine A in healthy volunteers. Methods Find Exp Clin Pharmacol 2006;28:25-9
92. Lin HL, Liu TY, Wu CW, Chi CW. Berberine modulates expression of mdr1 gene product and the responses of the digestive tract cancers to Paclitaxel. Br J Cancer 1999;81:416-22
93. Vrzal R, Zdarilova A, Ulrichova J, et al. Activation of the arylhydrocarbon receptor by berberine in HepG2 and H4IIEcells: biphasic effect on CYP1A1. Biochem Pharmacol 2005;70:925-36 (Pubitemid 41138858)
94. Deng R. Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc Drug Rev 2007;25(4):375-90 (Pubitemid 350233357)
95. Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia. A randomized, controlled trial. JAMA 2003;290:765-72 (Pubitemid 37432953)
96. Ulbricht C, Basch E, Szapary P, Natural Standard Research Collaboration. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med 2005;13(4):279-90 (Pubitemid 43024873)
97. Dalvi SS, Nayak VK, Pohujani SM, et al. Effect of gugulipid on bioavailability of diltiazem and propranolol. J Assoc Physicians India 1994;42:454-5
98. Menon VP, Sudheer AR. Anti-oxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 2007;595:105-25
99. Aggarval BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007;595:1-75
100. Kang Q, Chen A. Curcumin suppresses expression of low-density lipoprotein receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. Br J Pharmacol 2009;157:1354-67
101. Feng D, Ohlsson L, Duan RD. Curcumin inhibits cholesterol uptake in caco-2 cells by down-regulation of NPC1L1 expression. Lipids Health Dis 2010;9:40
102. Aggarwal BB. Targetting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 2010;30:173-99
103. Speciale A, Chirafisi J, Saija A, Cimino F. Nutritional antioxidants and adaptive cell responses: an update. Curr Mol Med 2011;11(9):770-89
104. Li G, Lin W, Araya JJ, et al. A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. Toxicol Appl Pharmacol 2012;258(2):268-74
105. Tokunaga S, White IR, Frost C, et al. Green tea consumption and serum lipids and lipoproteins in a population of healthy workers in Japan. Ann Epidemiol 2002;12:157-65 (Pubitemid 34189717)
106. Kim A, Chiu A, Barone MK, et al. Green tea catechins decrease total and low-density lipoprotein cholesterol: a systematic review and meta-analysis. J Am Diet Assoc 2011;111:1720-9
107. Zheng XX, Xu YL, Li SH, et al. Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials. Am J Clin Nutr 2011;94:601-10
108. Samman S, Sandstrom B, Toft MB, et al. Green tea or rosemary extract added to foods reduces nonheme-iron absorption. Am J Clin Nutr 2001;73:607-12 (Pubitemid 32176513)
109. Shirashi M, haruna M, Matsuzaki M, et al. Association between serum folate levels and tea consumption during pregnancy. Biosci Trends 2010;4:225-30
110. Rubenfire M, Brooke RD, Rosenson RS. Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am J Med 2010;123:892-8
111. Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 2003;23:151-2 (Pubitemid 36231919)
112. Cicero AFG De Sando V, Parini A, Borghi C. Polyunsaturated fatty acids application in internal medicine: beyond the established cardiovascular effects. Arch Med Sci 2012; In press
113. Djousse L, Gaziano JM, Buring JE, Lee IM. Dietary omega-3 fatty acids and fish consumption and risk of type 2 diabetes. Am J Clin Nutr 2011;93:143-50
114. Nettleton JA, Katz R. N-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet Assoc 2005;105:428-40 (Pubitemid 40326734)
115. Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. Br Med J 2006;332:752-60
116. Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol 2007;99(6A):44C-6C
117. Guallar E, Sanz-Gallardo MI, van't Veer P, et al. Mercury, fish oils, and the risk of myocardial infarction. Heavy Metals and Myocardial Infarction Study Group. N Engl J Med 2002;347:1747-54 (Pubitemid 35375613)
118. Eliat-Adar S, Goldbourt U. Nutritional recommendations for preventing coronary heart disease in women: evidence concerning whole foods and supplements. Nutr Metab Cardiovasc Dis 2010;20:459-66
119. Cohen JT, Bellinger DC, Connor WE, et al. A quantitative risk-benefit analysis of changes in population fish consumption. Am J Prev Med 2005;29:325-34 (Pubitemid 41483542)
120. Trimarco B, Benvenuti C, Rozza F, et al. Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet. Med J Nutr Metab 2011;4(2):133-9
121. Affuso F, Ruvolo A, Micillo F, et al. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis 2010;20:656-61